{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:44:14Z","timestamp":1787499854789,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12872-016-0241-3","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T19:32:37Z","timestamp":1461612757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies"],"prefix":"10.1186","volume":"16","author":[{"given":"S.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Roso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pladevall-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,26]]},"reference":[{"issue":"25 Pt B","key":"241_CR1","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"241_CR2","doi-asserted-by":"crossref","unstructured":"Yusuf S, Reddy S, \u00d4unpuu S, Anand S. Global burden of cardiovascular diseases, Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001b;104(23):2855\u201364.","DOI":"10.1161\/hc4701.099488"},{"key":"241_CR3","first-page":"CD004371","volume":"3","author":"A Schedlbauer","year":"2010","unstructured":"Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371. doi: 10.1002\/14651858.CD004371.pub3 .","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"241_CR4","first-page":"1635","volume":"13","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, European Association for Cardiovascular Prevention and Rehabilitation (EACPR), ESC Committee for Practice, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;13(13):1635\u2013701. doi: 10.1093\/eurheartj\/ehs092 . Epub 2012 May 3.","journal-title":"Eur Heart J"},{"key":"241_CR5","first-page":"1","volume-title":"Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease","author":"A Cooper","year":"2008","unstructured":"Cooper A, Nherera L, Calvert N, O\u2019Flynn N, Turnbull N, Robson J, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008. p. 1\u2013236 (revised March 2010)."},{"key":"241_CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)62027-3","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390.","journal-title":"Lancet"},{"key":"241_CR7","first-page":"CD004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"241_CR8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","volume":"18","author":"VG Athyros","year":"2002","unstructured":"Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The Greek Atorvastatin And Coronaryheart-Disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220\u20138.","journal-title":"Curr Med Res Opin"},{"key":"241_CR9","volume-title":"Risk estimation and the prevention of cardiovascular disease. A national clinical guideline","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2007","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 2007. Available at: http:\/\/www.sign.ac.uk\/pdf\/sign97.pdf. Accessed 1 November 2009."},{"issue":"1","key":"241_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.9.1","volume":"9","author":"Y Hata","year":"2002","unstructured":"Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias, et al. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb. 2002;9(1):1\u201327.","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"241_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","volume":"20","author":"T Teramoto","year":"2013","unstructured":"Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Japan Atherosclerosis Society, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20142012 version. J Atheroscler Thromb. 2013;20(6):517\u201323.","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"241_CR12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, B\u00e9gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"241_CR13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","volume":"166","author":"WM Mampuya","year":"2013","unstructured":"Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, Cho L. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166(3):597\u2013603. doi: 10.1016\/j.ahj.2013.06.004 . Epub 2013 Aug 5.","journal-title":"Am Heart J"},{"issue":"7","key":"241_CR14","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"241_CR15","volume-title":"Management of dyslipidemia in the prevention of vascular complications. Joint Consensus Statement of Austrian eight professional societies","author":"Austrian Lipid Consensus","year":"2010","unstructured":"Austrian Lipid Consensus. Management of dyslipidemia in the prevention of vascular complications. Joint Consensus Statement of Austrian eight professional societies. 2010. http:\/\/www.oedg.org\/pdf\/Lipidkonsensus_2010.pdf (20 May 2014, date last accessed)."},{"issue":"3\u20134","key":"241_CR16","first-page":"96","volume":"18","author":"K Huber","year":"2011","unstructured":"Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, et al. Practical implementation of the guidelines for LDL-lowering. J Cardiol. 2011;18(3\u20134):96\u20139.","journal-title":"J Cardiol"},{"key":"241_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1747-4949.2010.00429.x","volume":"5","author":"GJ Hankey","year":"2010","unstructured":"Hankey GJ, Wong KSL, Chankrachang S, Chen C, Crimmins D, Frayne J, et al. Management of cholesterol to reduce the burden of stroke in Asia: consensus statement. Int J Stroke. 2010;5:209\u201316.","journal-title":"Int J Stroke"},{"issue":"27","key":"241_CR18","first-page":"467","volume":"11","author":"N Rodondi","year":"2011","unstructured":"Rodondi N, Gencer B, Collet TH, Battegay E. Ab welchem Cholesterinwert soll in der Schweiz eine Behandlung erfolgen? Schweiz Med Forum. 2011;11(27):467\u201372.","journal-title":"Schweiz Med Forum"},{"key":"241_CR19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227\u201339.","journal-title":"Circulation"},{"key":"241_CR20","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, Backer GD, Graham I, Taskinen MR, Wiklund O. ESC\/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"issue":"5","key":"241_CR21","first-page":"26","volume":"14","author":"N Butler","year":"2010","unstructured":"Butler N. National guidelines at a glance: hypercholesterolaemia. Prof Nursing Today. 2010;14(5):26\u201331.","journal-title":"Prof Nursing Today"},{"key":"241_CR22","first-page":"195","volume":"15","author":"A Gami","year":"2006","unstructured":"Gami A. Secondary prevention of ischaemic cardiac events. Clin Evid. 2006;15:195\u2013228.","journal-title":"Clin Evid"},{"key":"241_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","volume":"29","author":"TJ Anderson","year":"2013","unstructured":"Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151\u201367.","journal-title":"Can J Cardiol"},{"issue":"1","key":"241_CR24","first-page":"48","volume":"57","author":"EE Chung","year":"2008","unstructured":"Chung EE. Best practice guidelines for treatment of hypercholesterolaemia: a statement from the Caribbean Cardiac Society. West Indian Med J. 2008;57(1):48\u201353.","journal-title":"West Indian Med J"},{"issue":"5","key":"241_CR25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1185\/030079907X187847","volume":"23","author":"B Ilerigelen","year":"2007","unstructured":"Ilerigelen B, Uresin Y, San M, K\u00fclt\u00fcrsay H, G\u00fcneri S, Serdar OA, et al. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). Curr Med Res Opin. 2007;23(5):1093\u2013102.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"241_CR26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0828-282X(06)70916-3","volume":"22","author":"KC Maki","year":"2006","unstructured":"Maki KC, Davidson MH, Dicklin MR. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II Survey. Can J Cardiol. 2006;22(4):315\u201322.","journal-title":"Can J Cardiol"},{"issue":"13","key":"241_CR27","first-page":"1187","volume":"21","author":"C Bourgault","year":"2005","unstructured":"Bourgault C, Davignon J, Fodor G, Gagn\u00e9 C, Gaudet D, Genest J, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study\u2014Observational (CALIPSO). Can J Cardiol. 2005;21(13):1187\u201393.","journal-title":"Can J Cardiol"},{"issue":"2","key":"241_CR28","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.25011\/cim.v30i2.981","volume":"30","author":"P Farahani","year":"2007","unstructured":"Farahani P, Levine M, Gaebel K, LeLorier J, Perrault S, Gillis J, et al. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care. Clin Invest Med. 2007;30(2):E63\u20139.","journal-title":"Clin Invest Med"},{"issue":"10","key":"241_CR29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0003319713512414","volume":"65","author":"M Arafah","year":"2014","unstructured":"Arafah M, Al-Hinai AT, Mahmeed WA, Al-Rasadi K, Al Tamimi O, Al Herz S, et al. Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries. Angiology. 2014;65(10):919\u201326. doi: 10.1177\/0003319713512414 . Epub 2013 Dec 3.","journal-title":"Angiology"},{"issue":"3","key":"241_CR30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1590\/S0066-782X2005001600003","volume":"85","author":"LJ Vacanti","year":"2005","unstructured":"Vacanti LJ, Santos SC, Fujita AM, Lima DS, Lopes AF, Vetorazi R, et al. Low rate of achieving LDL-cholesterol objective in a low income population. Arq Bras Cardiol. 2005;85(3):162\u20135.","journal-title":"Arq Bras Cardiol"},{"issue":"9","key":"241_CR31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00044011-200727090-00006","volume":"27","author":"G Paragh","year":"2007","unstructured":"Paragh G, Mark L, Zamolyi K, Pados G, Ofner P. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clin Drug Investig. 2007;27(9):647\u201360.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"241_CR32","first-page":"325","volume":"18","author":"F Raal","year":"2007","unstructured":"Raal F, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007;18(5):325\u20139.","journal-title":"Cardiovasc J Afr"},{"key":"241_CR33","first-page":"509","volume":"4","author":"G Michel","year":"2008","unstructured":"Michel G, Muller P. Pan-European survey on the undertreatment of hypercholesterolemia in hypolipidemias (Luxembourg). Bull Soc Sci Med Grand Duche Luxemb. 2008;4:509\u201316.","journal-title":"Bull Soc Sci Med Grand Duche Luxemb"},{"issue":"5","key":"241_CR34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/01.hjr.0000189805.76482.6e","volume":"13","author":"G Assmann","year":"2006","unstructured":"Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians\u2019 Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13(5):776\u201383.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"1","key":"241_CR35","first-page":"71","volume":"29","author":"M Munawar","year":"2013","unstructured":"Munawar M, Hartono B, Rifqi S. LDL cholesterol goal attainment in hypercholesterolemia: CEPHEUS Indonesian survey. Acta Cardiologica Sinica. 2013;29(1):71\u201381.","journal-title":"Acta Cardiologica Sinica"},{"issue":"5","key":"241_CR36","first-page":"395","volume":"18","author":"RH Chan","year":"2012","unstructured":"Chan RH, Chan PH, Chan KK, Lam SCC, Hai JJ, Wong MKL, et al. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Hong Kong Med J. 2012;18(5):395\u2013406.","journal-title":"Hong Kong Med J"},{"issue":"1","key":"241_CR37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","volume":"120","author":"DD Waters","year":"2009","unstructured":"Waters DD, Brotons C, Chiang CW, Ferri\u00e8res J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28\u201334.","journal-title":"Circulation"},{"issue":"1","key":"241_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCULATIONAHA.112.000500","volume":"128","author":"BM Egan","year":"2013","unstructured":"Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988\u20132010. Circulation. 2013;128(1):29\u201341.","journal-title":"Circulation"},{"issue":"2","key":"241_CR39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcma.2013.10.013","volume":"77","author":"KF Wang","year":"2014","unstructured":"Wang KF, Chang CC, Wang KL, Wu CH, Chen LC, Lu TM, et al. Determinants of low-density lipoprotein cholesterol goal attainment: insights from the CEPHEUS Pan-Asian Survey. J Chin Med Assoc. 2014;77(2):61\u20137.","journal-title":"J Chin Med Assoc"},{"issue":"8","key":"241_CR40","first-page":"544","volume":"38","author":"O Yiginer","year":"2010","unstructured":"Yiginer O, Ozmen N, Ozcelik F, Inan\u00e7 T, Karde\u015fo\u011flu E, Uz O, et al. Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: the role of education and knowledge. Turk Kardiyol Dern Ars. 2010;38(8):544\u201350.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"5","key":"241_CR41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.mlr.0000208017.18278.1a","volume":"44","author":"KA Foley","year":"2006","unstructured":"Foley KA, Denke MA, Kamal-Bahl S, Simpson Jr R, Berra K, Sajjan S, et al. The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. Med Care. 2006;44(5):421\u20138.","journal-title":"Med Care"},{"issue":"8","key":"241_CR42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-140-8-200404200-00013","volume":"140","author":"S Vijan","year":"2004","unstructured":"Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140(8):650\u20138.","journal-title":"Ann Intern Med"},{"issue":"9","key":"241_CR43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1157\/13093465","volume":"206","author":"A Gomez-Belda","year":"2006","unstructured":"Gomez-Belda A, Rodilla E, Gonzalez C, Costa JA, Serra B, Pascual JM. Lipid lowering goals in high risk and very high cardiovascular risk patients: a reasonable challenge? Rev Clin Esp. 2006;206(9):417\u201321.","journal-title":"Rev Clin Esp"},{"issue":"2","key":"241_CR44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11606-006-0253-2","volume":"21","author":"SD Persell","year":"2006","unstructured":"Persell SD, Lloyd-Jones DM, Baker DW. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med. 2006;21(2):171\u20136.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"241_CR45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2013.03.041","volume":"112","author":"ND Wong","year":"2013","unstructured":"Wong ND, Chuang J, Wong K, Pham A, Neff D, Marrett E. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009\u20132010). Am J Cardiol. 2013;112(3):373\u20139.","journal-title":"Am J Cardiol"},{"issue":"6","key":"241_CR46","first-page":"836","volume":"91","author":"W Nitiyanant","year":"2008","unstructured":"Nitiyanant W, Sritara P, Deerochanawong C, Ngarmukos P, Koanantakul B. Lipid treatment assessment project II in Thailand (LTAP-II Thailand). J Med Assoc Thai. 2008;91(6):836\u201345.","journal-title":"J Med Assoc Thai"},{"issue":"11","key":"241_CR47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/00044011-200525110-00004","volume":"25","author":"B Iglseder","year":"2005","unstructured":"Iglseder B, Moroder T, Staffen W, Ladurner G. High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig. 2005;25(11):709\u201317.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"241_CR48","first-page":"388","volume":"108","author":"M Gajdos","year":"2007","unstructured":"Gajdos M, Krivosikova Z, Uhliar R. A critical gap between recommended and achieved LDL-cholesterol levels. Results of statin therapy in Slovakia. Bratisl Lek Listy. 2007;108(9):388\u201392.","journal-title":"Bratisl Lek Listy"},{"issue":"3","key":"241_CR49","first-page":"A61","volume":"7","author":"UD Upadhyay","year":"2010","unstructured":"Upadhyay UD, Waddell EN, Young S, Kerker BD, Berger M, Matte T, et al. Prevalence, awareness, treatment, and control of high LDL cholesterol in New York City, 2004. Prev Chronic Dis. 2010;7(3):A61.","journal-title":"Prev Chronic Dis"},{"issue":"1","key":"241_CR50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4065\/83.1.35","volume":"83","author":"JM Flack","year":"2008","unstructured":"Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine\/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83(1):35\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"241_CR51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1524-6175.2005.04533.x","volume":"7","author":"R Blank","year":"2005","unstructured":"Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine\/atorvastatin Gemini study). J Clin Hypertens (Greenwich). 2005;7(5):264\u201373.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"241_CR52","unstructured":"Wang YR, Alexander GC, Meltzer DO. Screening and treatment of hypercholesterolemia for prevention of coronary heart disease. Manag Care Interface. 2006;19(1):25\u20139."},{"issue":"4","key":"241_CR53","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","volume":"96","author":"MH Davidson","year":"2005","unstructured":"Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556\u201363.","journal-title":"Am J Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0241-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:23:50Z","timestamp":1526639030000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-016-0241-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,26]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["241"],"URL":"https:\/\/doi.org\/10.1186\/s12872-016-0241-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,26]]},"article-number":"74"}}